ProKidney Corp. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; financial statements are unaudited. ProKidney is a clinical-stage biotechnology company developing REACT, an autologous renal-cell therapy for chronic kidney disease (CKD). It has no approved products and generated no revenue.
Financial position and results
| Metric | Q2 2023 / June 30, 2023 | Comparison |
|---|---|---|
| Revenue | None | No product revenue in either period |
| Research and development expense | $26.4 million | Up $14.8 million from Q2 2022 |
| General and administrative expense | $13.5 million | Up $4.3 million from Q2 2022 |
| Operating loss | $39.8 million | Q2 2022: $20.7 million |
| Net loss attributable to Class A shareholders | $9.1 million; $0.14 per share | Q2 2022: $22.1 million; prior-period per-share data not presented |
| Six-month net loss before noncontrolling interest | $71.7 million | Six months 2022: $89.6 million |
| Cash and cash equivalents | $243.6 million | December 31, 2022: $490.3 million |
| Marketable securities | $202.6 million | December 31, 2022: none reported |
| Current assets / current liabilities | $466.4 million / $24.5 million | |
| Total liabilities / lease liabilities | $27.3 million / $2.9 million | No material borrowings reported at June 30 |
Q2 interest income was $6.0 million; six-month interest income was $11.3 million. The company reported no meaningful operating margin because it had no revenue. The $1.78 billion redeemable noncontrolling interest reflects the exchangeable economic interest held by other PKLP unitholders, not conventional debt.
For the six months, operating cash use was $40.9 million versus $38.5 million in 2022. Investing cash use was $205.8 million, mainly purchases of marketable securities; financing cash use was negligible. Cash and cash equivalents declined by $246.7 million. Equity-based compensation was $24.2 million in the first half.
Material changes and unusual items
- Q2 R&D expense rose, principally from higher clinical-trial activity, hiring, equity compensation, and manufacturing work. Q2 G&A increased, including public-company legal and insurance costs.
- First-half total operating expenses fell to $80.7 million from $87.2 million. G&A declined by $18.4 million, chiefly because the 2022 period included substantially higher equity-based compensation; R&D increased by $11.9 million.
- Comparisons of net loss attributable to Class A shareholders require care: the business combination closed in July 2022, after the prior-year comparison period, and the 2023 statements separately allocate losses to noncontrolling interests.
- After quarter-end, on July 17, the company paid approximately $25.5 million for a 210,000-square-foot facility and land in Greensboro, North Carolina. Potential tax and energy incentives are conditional on investment and job-creation milestones.
Outlook, development and risks
- Management estimated that cash, cash equivalents and marketable securities on hand at June 30 would fund operating expenses and capital requirements through 2024, based on assumptions that could prove incorrect. The filing says additional funding will be needed; future financing could dilute shareholders or impose restrictive terms.
- REACT is in a Phase 3 program and multiple Phase 2 studies. ProKidney targeted interim RMCL-002 data in the second half of 2023 and REGEN-007 data around year-end 2023. It targeted a proact 1 interim analysis by the end of 2024, but warned the timing was at risk due to site staffing shortages, competition for trial sites and patients, changing CKD standard of care, and evolving regulatory guidance.
- Enrollment in planned Phase 3 REGEN-016 was expected to begin in the second half of 2023; the company anticipated interim data in late 2025. These are forward-looking targets, not guaranteed outcomes.
- Management expects R&D and G&A expenses to increase as trials progress and the business expands. Key uncertainties include trial enrollment and results, regulatory approval, manufacturing scale-up, supply-chain disruption, inflation, and access to capital. The company reported no material legal proceedings.
- Disclosure controls were assessed as effective as of June 30. A previously reported material weakness in accounting for complex financial instruments was remediated.
Investor verification priorities
- Check trial enrollment, interim readouts, endpoint results, and any changes to stated timelines—especially proact 1’s event-driven interim analysis.
- Reassess cash runway using actual spending, the $25.5 million post-quarter facility purchase, and the pace of future clinical and manufacturing investment.
- Verify the conditions, milestones, and expected timing for the announced facility incentives, which are not assured receipts.
- Review the allocation between Class A shareholders and PKLP noncontrolling holders, and the potential dilution from exchanges, equity awards, and earnout rights.
- Assess whether the company secures additional financing and whether trial, regulatory, manufacturing, or supply-chain developments alter its outlook.